Archives of clinical and biomedical research最新文献

英文中文

Assessment of Anterior Abdominal Wall Layers Thickness under the influence of Age and Sex, Using Computed Tomography Imaging in Ibn-Sina Hospital, Khartoum, Sudan 2021 在苏丹喀土穆Ibn-Sina医院使用计算机断层成像评估年龄和性别影响下的前腹壁层厚度

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170311

Ayman E Abbas, Mohammad Hatem Alrawi, Esra Ali Mahjoub Saeed

引用次数: 0

Clinical Value of NT-proBNP and Performance Myocardial Index as an Echocardiographic Predictor of Early Cardiac Involvement in Patients with Carcinoid Syndrome NT-proBNP和心肌功能指数作为类癌综合征患者早期心脏受累的超声心动图预测指标的临床价值

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170284

I. Nițu, I. Baciu, S. Găloiu, C. Căpăţană, Iulia Florentina Burcea, Daniela Greere, C. Poiană

引用次数: 0

Kartagener Syndrome Associated with a Family History of Dextrocardia – First Patient to be reported in Romania 卡塔赫纳综合征与右心家族史相关——罗马尼亚首例病例报道

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170285

A. Catană, Enikő Kutasi, Florica Ana Chis, Cristian Popiţa, Sanda Mariela Militaru

引用次数: 0

COVIDSeq as Laboratory Developed Test (LDT) for Diagnosis of SARS-CoV-2 Variants of Concern (VOC). covid - seq是实验室开发的诊断SARS-CoV-2关注变体(VOC)的测试(LDT)。

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170309

Rob E Carpenter, Vaibhav K Tamrakar, Sadia Almas, Emily Brown, Rahul Sharma

Rapid classification and detection of SARS-CoV-2 variants have been critical in comprehending the virus's transmission dynamics. Clinical manifestation of the infection is influenced by comorbidities such as age, immune status, diabetes, and the infecting variant. Thus, clinical management may differ for new variants. For example, some monoclonal antibody treatments are variant-specific. Yet, a U.S. Food and Drug Administration (FDA)-approved test for detecting the SARS-CoV-2 variant is unavailable. A laboratory-developed test (LDT) remains a viable option for reporting the infecting variant for clinical intervention or epidemiological purposes. Accordingly, we have validated the Illumina COVIDSeq assay as an LDT according to the guidelines prescribed by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA). The limit of detection (LOD) of this test is Ct<30 (~15 viral copies) and >200X genomic coverage, and the test is 100% specific in the detection of existing variants. The test demonstrated 100% precision in inter-day, intra-day, and intra-laboratory reproducibility studies. It is also 100% accurate, defined by reference strain testing and split sample testing with other CLIA laboratories. Advanta Genetics LDT COVIDSeq has been reviewed by CAP inspectors and is under review by FDA for Emergency Use Authorization.

快速分类和检测SARS-CoV-2变体对于了解该病毒的传播动态至关重要。感染的临床表现受合并症的影响，如年龄、免疫状况、糖尿病和感染变异。因此，对于新的变异，临床管理可能会有所不同。例如，一些单克隆抗体治疗是变异特异性的。然而，美国食品和药物管理局(FDA)批准的检测SARS-CoV-2变种的测试还没有。实验室开发的检测(LDT)仍然是报告感染变异以用于临床干预或流行病学目的的可行选择。因此，我们根据美国病理学家学会(CAP)和临床实验室改进修正案(CLIA)规定的指南，验证了Illumina covid - seq检测作为LDT。该检测的检测限(LOD)为Ct200X基因组覆盖率，检测现有变异的特异性为100%。该测试在日间、日间和实验室内的重复性研究中显示了100%的准确性。它也是100%准确的，通过参考应变测试和与其他CLIA实验室的分裂样品测试来定义。Advanta Genetics LDT covid - seq已通过CAP检查员的审查，并正在接受FDA的紧急使用授权审查。

{"title":"COVIDSeq as Laboratory Developed Test (LDT) for Diagnosis of SARS-CoV-2 Variants of Concern (VOC).","authors":"Rob E Carpenter, Vaibhav K Tamrakar, Sadia Almas, Emily Brown, Rahul Sharma","doi":"10.26502/acbr.50170309","DOIUrl":"https://doi.org/10.26502/acbr.50170309","url":null,"abstract":"Rapid classification and detection of SARS-CoV-2 variants have been critical in comprehending the virus's transmission dynamics. Clinical manifestation of the infection is influenced by comorbidities such as age, immune status, diabetes, and the infecting variant. Thus, clinical management may differ for new variants. For example, some monoclonal antibody treatments are variant-specific. Yet, a U.S. Food and Drug Administration (FDA)-approved test for detecting the SARS-CoV-2 variant is unavailable. A laboratory-developed test (LDT) remains a viable option for reporting the infecting variant for clinical intervention or epidemiological purposes. Accordingly, we have validated the Illumina COVIDSeq assay as an LDT according to the guidelines prescribed by the College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA). The limit of detection (LOD) of this test is Ct<30 (~15 viral copies) and >200X genomic coverage, and the test is 100% specific in the detection of existing variants. The test demonstrated 100% precision in inter-day, intra-day, and intra-laboratory reproducibility studies. It is also 100% accurate, defined by reference strain testing and split sample testing with other CLIA laboratories. Advanta Genetics LDT COVIDSeq has been reviewed by CAP inspectors and is under review by FDA for Emergency Use Authorization.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802674/pdf/nihms-1854775.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10475770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Knowledge Distillation for COVID-19 Therapeutics COVID-19疗法的知识提炼

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170233

Shiyao Zhai, Yuhan Gao, Kailai Peng, Qun Chen, Qian He, Li Fang, Linling Li, Bowen Zhong, Yu-Ying Dong, Chenggang Yan, Peiwu Qin, D. Y

The novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 is threatening the world's economy and healthcare with urgent therapeutic demand. Clinical and scientific studies have made promising progress in ameliorating and treating COVID-19. The unprecedented effort has brought several vaccines approved for emergency use, and prevalent vaccination is advocated globally. However, methods that can effectively clear the virus and terminate transmission are not available. The variants and uncontrolled circulations bring persistent challenges Arch Clin Biomed Res 2022; 6 (1): 153-183 DOI: 10.26502/acbr.50170233 Archives of Clinical and Biomedical Research Vol. 6 No.1 – February 2022. [ISSN 2572-9292]. 154 for therapeutics and vaccines. In this review, we discuss the ongoing treatments, the mechanism, and potential optimization of various therapeutics. We review the viral pathogenesis and epidemiology and provide insights for prospective therapeutics and vaccine evolution, which will help clinical doctors and researchers in this pandemic.

由严重急性呼吸综合征冠状病毒2型引起的新型冠状病毒病(COVID-19)威胁着世界经济和卫生保健，治疗需求迫切。临床和科学研究在缓解和治疗新冠肺炎方面取得了可喜进展。这一前所未有的努力已使几种疫苗获批用于紧急用途，并在全球提倡普遍接种疫苗。然而，目前还没有能够有效清除病毒并终止传播的方法。变体和不受控制的循环带来了持续的挑战;6 (1): 153-183 DOI: 10.26502/acbr.50170233临床和生物医学研究档案第6卷第1期- 2022年2月。(ISSN 2572 - 9292)。154用于治疗和疫苗。在这篇综述中，我们讨论了正在进行的治疗，机制，以及各种治疗方法的潜在优化。我们回顾了病毒的发病机制和流行病学，并提供了前瞻性治疗和疫苗进化的见解，这将有助于临床医生和研究人员应对这次大流行。

{"title":"Knowledge Distillation for COVID-19 Therapeutics","authors":"Shiyao Zhai, Yuhan Gao, Kailai Peng, Qun Chen, Qian He, Li Fang, Linling Li, Bowen Zhong, Yu-Ying Dong, Chenggang Yan, Peiwu Qin, D. Y","doi":"10.26502/acbr.50170233","DOIUrl":"https://doi.org/10.26502/acbr.50170233","url":null,"abstract":"The novel coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 is threatening the world's economy and healthcare with urgent therapeutic demand. Clinical and scientific studies have made promising progress in ameliorating and treating COVID-19. The unprecedented effort has brought several vaccines approved for emergency use, and prevalent vaccination is advocated globally. However, methods that can effectively clear the virus and terminate transmission are not available. The variants and uncontrolled circulations bring persistent challenges Arch Clin Biomed Res 2022; 6 (1): 153-183 DOI: 10.26502/acbr.50170233 Archives of Clinical and Biomedical Research Vol. 6 No.1 – February 2022. [ISSN 2572-9292]. 154 for therapeutics and vaccines. In this review, we discuss the ongoing treatments, the mechanism, and potential optimization of various therapeutics. We review the viral pathogenesis and epidemiology and provide insights for prospective therapeutics and vaccine evolution, which will help clinical doctors and researchers in this pandemic.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69340184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of the Earliness of Detection and Notification of Major Infectious Threats to Global Health Security in Benin 评估贝宁对全球卫生安全重大传染病威胁的早期发现和通报情况

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170235

Vincent Dossou Sodjinou, Paul Ahoumènou AYELO, L. Salami, A. Kpozèhouen, Dona Marius-Edgard Ouendo

Introduction Early detection and notification can reduce morbidity and mortality from an event.

早期发现和通报可降低事件的发病率和死亡率。

引用次数: 0

Obesity and diabetes are the strongest predictors of post-acute COVID-19 in Coptic clergy and monks 肥胖和糖尿病是科普特神职人员和僧侣急性后COVID-19的最强预测因素

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170252

Michael Y. Henein, R. Shenouda, Magdi Z. Matter, I. Bytyçi

引用次数: 0

Effect of Short Term High Dose Oral Vitamin D Therapy on the Inflammatory Markers in Patients with COVID 19 Disease 短期大剂量口服维生素D治疗对新冠肺炎患者炎症标志物的影响

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170273

Maheshwar Lakkireddy, Srikanth Goud Gadiga, R. Malathi, Madhu Latha Karra, Issv Prasad Murthy Raju, Ragini, Sangeetha Chinapaka, Sai Baba KSS, Manohar Kandakatla

Introduction: COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the effect of short term high dose vitamin D therapy in reducing the inflammatory markers of COVID-19. Materials and Methods: Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0 th day and 9 th / 11 th day as per their respective BMI category. Subjects were allotted to VD and NVD groups. VD group received Pulse D therapy (a short term high dose supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Results: Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from 15 ng/ml to 81 ng/ml in VD group and highly significant (p<0.01) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant (p>0.05). The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p<0.01). Conclusions: Therapeutic improvement in vitamin D to 80-100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. Hence, adjunctive short term high dose vitamin D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.

导语:已知COVID - 19会导致免疫失调，维生素D是已知的免疫调节剂。本研究旨在客观探讨短期高剂量维生素D治疗对降低COVID-19炎症标志物的作用。材料与方法:在第0天和第9 / 11天，根据各自的BMI分类，评估COVID-19合并维生素D缺乏症患者的炎症标志物(N/L比值、CRP、LDH、il - 6、铁蛋白)和维生素D。受试者被分为VD组和NVD组。VD组在标准治疗的基础上接受脉冲D治疗(根据他们的BMI，短期高剂量补充60000国际单位的维生素D，持续8天或10天)。NVD组单独给予标准治疗。分析两组间变量的差异有无统计学意义。结果:130名受试者中有87人完成了研究(VD:44, NVD:43)。VD组维生素D水平由15 ng/ml升高至81 ng/ml，且极显著(p0.05)。两组间(NVD vs VD)标志物减少量差异极显著(p<0.01)。结论:维生素D治疗改善至80-100 ng/ml可显著降低与COVID-19相关的炎症标志物，且无任何副作用。因此，可以安全地将短期高剂量维生素D辅助治疗添加到现有的COVID-19治疗方案中，以改善结果。

{"title":"Effect of Short Term High Dose Oral Vitamin D Therapy on the Inflammatory Markers in Patients with COVID 19 Disease","authors":"Maheshwar Lakkireddy, Srikanth Goud Gadiga, R. Malathi, Madhu Latha Karra, Issv Prasad Murthy Raju, Ragini, Sangeetha Chinapaka, Sai Baba KSS, Manohar Kandakatla","doi":"10.26502/acbr.50170273","DOIUrl":"https://doi.org/10.26502/acbr.50170273","url":null,"abstract":"Introduction: COVID 19 is known to cause immune dysregulation and vitamin D is a known immunomodulator. This study aims to objectively investigate the effect of short term high dose vitamin D therapy in reducing the inflammatory markers of COVID-19. Materials and Methods: Consented COVID-19 patients with hypovitaminosis D were evaluated for inflammatory markers (N/L ratio, CRP, LDH, IL6, Ferritin) along with vitamin D on 0 th day and 9 th / 11 th day as per their respective BMI category. Subjects were allotted to VD and NVD groups. VD group received Pulse D therapy (a short term high dose supplementation of 60,000 IUs of vitamin D for 8 or 10 days depending upon their BMI) in addition to the standard treatment. NVD group received standard treatment alone. Differences in the variables between the two groups were analysed for statistical significance. Results: Eighty seven out of one hundred and thirty subjects have completed the study (VD:44, NVD:43). Vitamin D level has increased from 15 ng/ml to 81 ng/ml in VD group and highly significant (p<0.01) reduction of all the measured inflammatory markers was noted. Reduction of markers in NVD group was insignificant (p>0.05). The difference in the reduction of markers between the groups (NVD vs VD) was highly significant (p<0.01). Conclusions: Therapeutic improvement in vitamin D to 80-100 ng/ml has significantly reduced the inflammatory markers associated with COVID-19 without any side effects. Hence, adjunctive short term high dose vitamin D therapy can be added safely to the existing treatment protocols of COVID-19 for improved outcomes.","PeriodicalId":72279,"journal":{"name":"Archives of clinical and biomedical research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69340881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Medical Education During COVID 19 Pandemic: A Trainees Experiences COVID - 19大流行期间的医学教育:一名学员的经历

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170270

Abdalazeem Ibrahem, Tarig A Mohamed, H. Elzein

引用次数: 0

Estimation of COVID-19 Cases in Japanese Prefectures Using a Gumbel Distribution 用甘贝尔分布估计日本各县COVID-19病例

Archives of clinical and biomedical research

Pub Date : 2022-01-01 DOI: 10.26502/acbr.50170288

Hiroshi Furutani, T. Hiroyasu

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Archives of clinical and biomedical research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀